Scientists find a safer way to make cells burn more calories
January 5, 2026 / mitochondrial calorie burning / obesity treatment research / weight loss compounds / cellular metabolism boosters / safe fat burning
Scientists have created safer mitochondrial-targeting compounds that increase cellular calorie burning without the dangerous side effects of past weight-loss drugs, offering potential for future obesity treatments and improved metabolic health.
Weight loss drugs fall short on obesity-related cancer risk
December 31, 2025 / GLP-1 cancer risk / obesity-related cancer / Ozempic cancer study / weight loss drugs / metabolic health drugs
GLP-1 drugs like Ozempic and Zepbound effectively support weight and heart health but show no meaningful impact on reducing obesity-related cancer risk, according to a large meta-analysis of clinical trials. Longer-term cancer-focused studies are needed.
One of the Most Common Diabetes Treatments May Be Making the Disease Worse, Study Warns
January 3, 2026 / sulphonylureas diabetes risk / beta cell dysfunction / type 2 diabetes treatment / insulin production loss / diabetes drug side effects
New research suggests sulphonylureas, a common type 2 diabetes treatment, may accelerate disease progression by causing pancreatic beta cells to lose their insulin-producing identity, potentially reducing long-term effectiveness and worsening metabolic control.
Golden Berry (Physalis peruviana): Anti-Inflammatory Properties and Emerging Evidence for Metabolic Health
January 4, 2026 / golden berries inflammation / metabolic health berries / insulin resistance natural / NF-kB antioxidant effects / goldenberry diabetes support
Golden berries (Physalis peruviana) show preclinical promise for reducing inflammation and improving metabolic health by modulating NF-κB signaling, lowering cytokines, and enhancing insulin sensitivity, though human clinical trials are needed for confirmation.
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease – Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
January 5, 2026 / DA-1726 obesity drug / GLP-1 glucagon dual / liver stiffness reduction / metabolic disease treatment / weight loss clinical trial
MetaVia’s DA-1726 showed statistically significant weight loss, improved glycemic control, and reduced liver stiffness in Phase 1b trial for obesity. The dual GLP-1/glucagon agonist demonstrated strong metabolic effects and a favorable safety profile over 8 weeks.
Surgeons: Obesity isn’t about willpower—it’s a treatable medical condition
January 5, 2026 / obesity treatment options / bariatric surgery benefits / GLP-1 weight loss / metabolic disease care / obesity stigma healthcare
Obesity is a complex, treatable medical condition—not a failure of willpower. Experts emphasize individualized care combining medication, surgery, and lifestyle changes for lasting results, especially in severe cases. Accurate information and expanded access to treatment are essential.
Exercise won’t help you lose much fat. Changing this will
January 1, 2026 / exercise fat loss / calorie burning myths / weight loss research / metabolic health tips / obesity and activity
New global research shows exercise has minimal impact on daily calorie burn and fat loss. Weight is more influenced by diet and metabolic regulation, though exercise still plays a vital role in overall health and disease prevention.
Scientists tested intermittent fasting without eating less and found no metabolic benefit
January 3, 2026 / intermittent fasting research / insulin sensitivity study / metabolic health findings / time-restricted eating / calorie reduction benefits
A study found that intermittent fasting without reducing calories did not improve insulin sensitivity or cardiovascular health, though it shifted circadian rhythms. This suggests calorie reduction, not meal timing alone, drives metabolic benefits.
Bacteria for weight loss? Research reveals gut microbe that boosts metabolism in mice
January 5, 2026 / gut microbiome obesity / Turicibacter metabolism weight / beneficial gut bacteria / ceramides fat metabolism / microbial weight loss
Researchers identified Turicibacter, a gut microbe that boosts metabolism and reduces weight gain in mice by lowering ceramide levels and producing beneficial lipids. This discovery may lead to future therapies targeting the microbiome to manage obesity.
Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions
January 2, 2026 / metabolic obesity biomarker / adipose microbiome interaction / metBMI cardiometabolic risk / obesity precision medicine / gut metabolome inflammation
A new metabolome-informed obesity metric (metBMI) better predicts cardiometabolic risk than BMI by capturing adipose tissue dysfunction and microbiome interactions, highlighting a bidirectional host–microbiome axis and enabling more precise obesity-related disease stratification and intervention.
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
December 30, 2025 / pemvidutide / MASH treatment / liver fibrosis biomarkers / FDA breakthrough therapy / metabolic liver disease
The FDA granted Breakthrough Therapy Designation to pemvidutide for MASH, based on Phase 2b data showing significant MASH resolution, liver fat reduction, and fibrosis biomarker improvements, supporting its advancement to Phase 3 clinical trials.
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
January 5, 2026 / pemvidutide / MASH treatment / liver fibrosis reduction / GLP-1 glucagon dual / FDA breakthrough designation
The FDA granted Breakthrough Therapy Designation to Altimmune’s pemvidutide for MASH, based on Phase 2b data showing significant MASH resolution, liver fat reduction, improved fibrosis biomarkers, sustained weight loss, and favorable tolerability over 48 weeks.
Pemvidutide advances toward Phase 3 after strong MASH fibrosis results
January 5, 2026 / pemvidutide / MASH fibrosis / liver fat reduction / GLP-1 GCGR dual / Phase 3 trial
Altimmune’s pemvidutide showed significant antifibrotic effects and liver fat reduction in MASH patients after 48 weeks, with favorable tolerability. These Phase 2b results support progression to a registrational Phase 3 trial starting in 2026.
Hepatic GPR110 contributes to sex disparity in the development of MASH through oestrogen receptor α-dependent signalling
January 5, 2026 / GPR110 MASH / sex differences liver disease / estrogen receptor alpha / metabolic steatohepatitis / precision MASH therapy
GPR110 drives sex-specific susceptibility to MASH by suppressing hepatic estrogen receptor α signaling. Female-specific GPR110 inhibition protects against steatohepatitis, identifying a potential precision, sex-tailored therapeutic target for MASH.
Lupin Obtains Exclusive Rights for Innovative͏ G͏LP-1Drug in In͏dia Through͏ Chinese͏ Partnership
December 30, 2025 / GLP-1 India launch / Bofanglutide diabetes obesity / Lupin Gan & Lee / fortnightly weight loss drug / chronic metabolic therapy
Lupin secured exclusive rights to market Bofanglutide, a novel once-fortnightly GLP-1 receptor agonist, in India for type 2 diabetes and obesity. The drug offers significant metabolic benefits with reduced injection frequency and aligns with India’s rising chronic disease burden.
Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drug
December 30, 2025 / Lupin GLP-1 partnership / Bofanglutide diabetes drug / Gan & Lee licensing deal / obesity treatment India / metabolic disease therapy
Lupin secured exclusive rights to distribute Bofanglutide, a novel once-fortnightly GLP-1 receptor agonist from Gan & Lee, for type 2 diabetes and obesity treatment in India, potentially enhancing its metabolic disease portfolio and market presence.
Sunshine and supplements shown to reverse obesity conditions
January 2, 2026 / vitamin D obesity treatment / sunlight metabolic health / liver fat reduction / weight loss supplements / cholesterol improvement therapy
Sunlight exposure and vitamin D3 supplementation significantly improved obesity-related markers in mice, including weight, blood glucose, cholesterol, and liver health, suggesting potential metabolic benefits beyond vitamin D alone and warranting further human research.
The autonomic nervous system in the regulation of glucose and lipid metabolism
January 5, 2026 / autonomic nervous system / glucose lipid metabolism / type 2 diabetes regulation / metabolic disease treatment / obesity nervous system
The autonomic nervous system regulates glucose and lipid metabolism through dynamic signaling with metabolic organs. Dysregulation contributes to diseases like obesity and type 2 diabetes, highlighting potential therapeutic targets and the need for improved organ-specific assessment tools.
Understanding childhood obesity: Causes, treatments and how to reduce stigma
December 30, 2025 / childhood obesity treatment / pediatric weight management / family-based interventions / early obesity screening / obesity stigma reduction
Childhood obesity is a complex condition influenced by genetics, environment, and behavior. Effective treatment requires early screening, family-centered lifestyle interventions, behavioral therapy, and sometimes medication or surgery—while reducing stigma through compassionate, inclusive care.
New Insulin Resistance Limits Redefine Metabolic Syndrome
January 3, 2026 / insulin resistance thresholds / metabolic syndrome assessment / body composition indices / cardiovascular risk biomarkers / obesity and metabolism
A new study redefines insulin resistance thresholds in metabolic syndrome by integrating advanced body composition indices, offering improved assessment tools beyond BMI to better capture metabolic risk and guide clinical decision-making.